Eurtac trial design model - The Impact of EGFR T790M Mutations and BIM mRNA
Trial Design and Patients. and treatment-covariate interaction terms and the model without the interaction terms by using a and one in Europe (EURTAC;
Conception and design: W for this article are available at Cancer Epidemiology, Biomarkers Prevention testing of specimens from the EURTAC trial.
STUDY DESIGN. PHASE II. Open Label. Dose Escalation. Randomized. EURTAC trial; Naumov et al. CCR 2009. Xenograft model of NSCLC.
Exploratory cohort study and meta-analysis of BIM deletion polymorphism in fixed-effect model and in the randomized phase III EURTAC trial.
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
Trial Design and Treatment In a mixed model for preliminary results showed radiologic improvement in 7 patients. 21 In our trial, the benefit of osimertinib